You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

envafolimab

Showing 26 - 50 of 52
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Cancer Trial in Nanchang (High- and Low-dose radiotherapy)

Recruiting
  • Metastatic Cancer
  • High- and Low-dose radiotherapy
  • Nanchang, Jiangxi, China
  • +1 more
Mar 6, 2023

Non-Small-Cell Lung Trial in Xi'an (Envafolimab;Pemetrexed)

Not yet recruiting
  • Non-Small-Cell Lung
  • Xi'an, Shanxi, China
    The First Affiliated Hospital of Xian Jiaotong University
Jul 17, 2022

NSCLC Trial (Almonertinib Envafolimab)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Almonertinib Envafolimab
  • (no location specified)
Sep 10, 2022

NSCLC Trial in Tianjing (Envalfolimab subcutaneously injected+Platinum-based doublet chemo intravenous injection,

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
  • placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
  • Tianjing, Tianjin, China
    Tianjin cancer hospital
Nov 3, 2023

Gastric/Gastroesophageal Junction Adenocarcinoma, Radiotherapy, Immunotherapy Trial (Envafolimab)

Not yet recruiting
  • Gastric/Gastroesophageal Junction Adenocarcinoma
  • +2 more
  • Envafolimab
  • (no location specified)
May 18, 2022

Biliary Tract Tumors Trial (Envafolimab plus Gemcitabine&Cisplatin, Gemcitabine&Cisplatin)

Not yet recruiting
  • Biliary Tract Neoplasms
  • (no location specified)
Jun 8, 2022

Advanced Endometrial Cancer Trial in China (Envafolimab+Lenvatinib, Envafolimab)

Recruiting
  • Advanced Endometrial Cancer
  • Beijing, Beijing, China
  • +18 more
Jan 2, 2023

Metastatic or Recurrent Gastric Adenocarcinoma Trial in Nanjing (Envafolimab, Oxaliplatin, S1)

Recruiting
  • Metastatic or Recurrent Gastric Adenocarcinoma
  • Envafolimab
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Institute & Hospital
Apr 19, 2022

Ovarian Cancer, Epithelial Trial in Nanjing (Envafolimab, Lenvatinib, VP-16)

Not yet recruiting
  • Ovarian Cancer, Epithelial
  • Envafolimab
  • +2 more
  • Nanjing, Jiangsu, China
    Zhongda Hospital
Jun 13, 2022

NSCLC Stage III Trial in Hefei (Envafolimab)

Not yet recruiting
  • Non-small Cell Lung Cancer Stage III
  • Envafolimab
  • Hefei, Anhui, China
    Anhui Provincial Cancer Hospital
Jun 8, 2022

Rectal Cancer Trial in Fuzhou (radiation, drug, procedure)

Not yet recruiting
  • Rectal Cancer
  • split-course hypofraction radiotherapy
  • +3 more
  • Fuzhou, Fujian, China
    Pan Chi
Jul 23, 2023

Colon Cancer Trial (Envafolimab)

Not yet recruiting
  • Colon Cancer
  • Envafolimab
  • (no location specified)
Apr 13, 2022

Advanced Pancreatic Cancer Trial in Xuzhou (Envafolimab, Endostar, Nab paclitaxel)

Not yet recruiting
  • Advanced Pancreatic Cancer
  • Envafolimab
  • +3 more
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Mar 18, 2022

Advanced Hepatocellular Carcinoma Trial in Hangzhou (Envafolimab, TACE, Lenvatinib)

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Envafolimab
  • +2 more
  • Hangzhou, Zhejiang, China
    the First Affiliated Hospital, School of Medicine, Zhejiang Univ
Mar 13, 2022

Lung Tumors Trial (Envafolimab, Endostar)

Not yet recruiting
  • Lung Neoplasms
  • (no location specified)
Feb 8, 2022

Squamous NSCLC Trial in Jinan ("Envafolimab" and "Chemotherapy" and "Recombinant Human Endostatin")

Recruiting
  • Squamous Non-small Cell Lung Cancer
  • "Envafolimab" and "Chemotherapy" and "Recombinant Human Endostatin"
  • Jinan, Shandong, China
  • +1 more
Feb 14, 2022

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

Recruiting
  • Colorectal Cancer
  • +3 more
  • Neoadjuvant therapy with PD-L1 inhibitor
  • Guangzhou, Guangdong, China
    the Third Affiliated Hospital of Sun Yat-Sen University
May 10, 2022

NSCLC Trial in Changsha (envafolimab)

Enrolling by invitation
  • Non-small Cell Lung Cancer
  • envafolimab
  • Changsha, Hunan, China
    the second Xiangya hospital
May 1, 2022

Colon Cancer, Neoadjuvant Therapy, Immunotherapy Trial in Guangzhou (Envafolimab, CAPEOX)

Recruiting
  • Colon Cancer
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Aug 26, 2023

NSCLC Stage IV Trial in Xiamen (Envafolimab)

Active, not recruiting
  • Non-small Cell Lung Cancer Stage IV
  • Envafolimab
  • Xiamen, Fujian, China
    First affiliated Hospital of Xiamen University
Sep 14, 2021

Colon Tumor Trial in Hangzhou (Oxaliplatin, Capecitabine, Anti-PD-L1 Monoclonal Antibody)

Not yet recruiting
  • Colon Neoplasm
  • Hangzhou, Zhejiang, China
    Second Affiliated Hospital of Zhejiang University School of Medi
Jun 25, 2023

Non Small Cell Lung Cancer Trial in China (Chidamide, Envafolimab)

Recruiting
  • Non Small Cell Lung Cancer
  • Hefei, Anhui, China
  • +11 more
Jan 17, 2022

Biliary Tract Cancer Trial (RC48-ADC, Envafolimab)

Not yet recruiting
  • Biliary Tract Cancer
  • (no location specified)
Jun 9, 2022

Solid Tumors, NSCLC, Renal Cell Carcinoma Trial in China (Lenvatinib + Envafolimab, Sunitinib)

Recruiting
  • Solid Tumors
  • +3 more
  • Benbu, Anhui, China
  • +22 more
Jun 28, 2022

Malignant Tumors Trial in Guangzhou (LM101, Toripalimab, Rituximab)

Recruiting
  • Malignant Tumors
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jan 17, 2023